Skip to main content
Equibles

ASTRAZEN · AstraZeneca Pharma India Limited · Financials

Use ASTRAZEN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ASTRAZEN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
6,031.50 INR -407.00 (-6.32%) At close · Nov 13
Rebalance outlook locked
Market Cap
150.79B INR
Shares
25.00M
Volume · Nov 13 33.31K Avg daily vol (3M) 11.49K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
22.76B +32.6%
FY2026 Revenue FY2019–FY2026
Net Income
1.88B +62%
FY2026 Net Income FY2019–FY2026
Operating Cash Flow
-151.4M -123.2%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
INR 26.02B 22.76B 17.16B 12.96B 10.03B 8.06B 8.14B 8.32B 7.28B
INR 200.2M 285.8M 399.9M 149.41M 162.6M 169.49M 201.26M 185.84M 149.24M
INR 69.4M 44.9M 14.6M 12.01M 6.33M 9.47M 10.93M 11.37M 0
INR 2.44B 2.52B 1.56B 2.2B 1.34B 830.36M 1.27B 1.14B 726.64M
INR 661.9M 646.8M 406.2M 580.26M 348.12M 214.43M 337.9M 417.5M 182.23M
INR 1.78B 1.88B 1.16B 1.62B 992.93M 615.93M 933.04M 722.11M 0
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 2.05B in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.